Pharmaceuticals stocks
86 US-listed companies in pharmaceuticals, with $591.9bn of combined revenue in their latest fiscal years. Johnson & Johnson is the largest ($94.2bn). The fastest grower with at least $100m of revenue in both years is Travere Therapeutics, Inc., up 110.5%. The median company grew 7.5% with a net margin of 7.1%.
Companies86
Combined revenue$591.9bn
Median revenue growth7.5%
Median net margin7.1%
Median return on equity10.4%
| # | Company | Revenue | Growth | Net margin | ROE | Fiscal year |
|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ | $94.2bn | 6.0% | 28.5% | 35.0% | 2025 |
| 2 | Lilly (Eli)LLY | $65.2bn | 44.7% | 31.7% | 101.2% | 2025 |
| 3 | Merck & Co.MRK | $65.0bn | 1.3% | 28.1% | 36.9% | 2025 |
| 4 | PfizerPFE | $62.6bn | −1.6% | 12.4% | 8.9% | 2025 |
| 5 | Astrazeneca PLCAZN | $58.7bn | 8.6% | 17.4% | 22.9% | 2025 |
| 6 | Bristol Myers SquibbBMY | $48.2bn | −0.2% | 14.6% | 40.5% | 2025 |
| 7 | Novo Nordisk A SNVO | $46.8bn | 11.1% | 33.1% | 61.6% | 2025 |
| 8 | GSK plcGSK | $43.1bn | 7.5% | 17.5% | 38.5% | 2025 |
| 9 | Universe Pharmaceuticals IncUPC | $17.9bn | −22.4% | −20.6% | −7.2% | 2025 |
| 10 | Haleon plcHLN | $14.6bn | 1.3% | 15.1% | 10.4% | 2025 |
| 11 | ViatrisVTRS | $14.3bn | −3.0% | −24.6% | −21.1% | 2025 |
| 12 | Bausch Health Companies Inc.BHC | $10.3bn | 6.7% | 1.5% | — | 2025 |
| 13 | ZoetisZTS | $9.5bn | 2.3% | 28.2% | 65.3% | 2025 |
| 14 | Organon & Co.OGN | $6.2bn | −2.9% | 3.0% | 30.6% | 2025 |
| 15 | Elanco Animal Health IncELAN | $4.7bn | 6.2% | −4.9% | −3.7% | 2025 |
| 16 | Jazz Pharmaceuticals plcJAZZ | $4.3bn | 4.9% | −8.3% | −8.5% | 2025 |
| 17 | Amneal Pharmaceuticals, Inc.AMRX | $3.0bn | 8.0% | 2.4% | — | 2025 |
| 18 | Royalty Pharma plcRPRX | $2.4bn | 5.1% | 32.4% | 7.7% | 2025 |
| 19 | Lantheus Holdings, Inc.LNTH | $1.5bn | 0.5% | 15.2% | 21.4% | 2025 |
| 20 | Phibro Animal Health CorpPAHC | $1.5bn | 17.1% | 6.6% | 29.7% | 2026 |
| 21 | Indivior Pharmaceuticals, Inc.INDV | $1.2bn | 4.3% | 16.9% | — | 2025 |
| 22 | Nasus Pharma LtdNSRX | $1.2bn | — | −0.5% | — | 2025 |
| 23 | Trulieve Cannabis Corp.TRLV | $1.2bn | −0.4% | −9.9% | −9.7% | 2025 |
| 24 | Prestige Consumer Healthcare Inc.PBH | $1.1bn | −4.3% | 17.5% | 10.2% | 2026 |
| 25 | ANI Pharmaceuticals IncANIP | $883m | 43.8% | 8.9% | 16.6% | 2025 |
| 26 | Harmony Biosciences Holdings, Inc.HRMY | $868m | 21.5% | 18.3% | 20.8% | 2025 |
| 27 | Collegium Pharmaceutical, IncCOLL | $781m | 23.6% | 8.1% | 23.7% | 2025 |
| 28 | Corcept Therapeutics IncCORT | $761m | 12.8% | 13.1% | 15.0% | 2025 |
| 29 | Emergent Biosolutions Inc.EBS | $743m | −28.8% | 7.1% | 10.5% | 2025 |
| 30 | Pacira Biosciences, Inc.PCRX | $726m | 3.6% | 1.0% | 1.0% | 2025 |
| 31 | Amphastar Pharmaceuticals, Inc.AMPH | $720m | −1.7% | 13.6% | 12.9% | 2025 |
| 32 | Supernus Pharmaceuticals, Inc.SUPN | $719m | 8.6% | −5.4% | −3.7% | 2025 |
| 33 | Axsome Therapeutics, Inc.AXSM | $638m | 65.5% | −28.7% | — | 2025 |
| 34 | Opko Health, Inc.OPK | $607m | −14.9% | −37.2% | −17.1% | 2025 |
| 35 | AlvotechALVO | $586m | 19.7% | 4.8% | — | 2025 |
| 36 | Travere Therapeutics, Inc.TVTX | $491m | 110.5% | −5.2% | −29.4% | 2025 |
| 37 | Innoviva, Inc.INVA | $411m | 14.7% | 65.9% | 29.1% | 2025 |
| 38 | Evolus, Inc.EOLS | $297m | 11.6% | −17.4% | — | 2025 |
| 39 | Ironwood Pharmaceuticals IncIRWD | $296m | −15.7% | 8.1% | — | 2025 |
| 40 | Rigel Pharmaceuticals IncRIGL | $294m | 64.1% | 124.7% | 185.9% | 2025 |
| 41 | Xeris Biopharma Holdings, Inc.XERS | $292m | 43.7% | 0.2% | — | 2025 |
| 42 | Harrow, Inc.HROW | $272m | 36.4% | −1.9% | −8.4% | 2025 |
| 43 | Aurora Cannabis IncACB | $232m | 11.7% | −42.4% | −25.9% | 2026 |
| 44 | Vanda Pharmaceuticals Inc.VNDA | $216m | 8.7% | −102.0% | −50.9% | 2025 |
| 45 | Amarin Corp plc\ukAMRN | $214m | −6.5% | −18.2% | −8.2% | 2025 |
| 46 | Biote Corp.BTMD | $192m | −2.5% | 14.1% | — | 2025 |
| 47 | Organigram Global Inc.OGI | $185m | 57.8% | −9.6% | −7.4% | 2025 |
| 48 | Kamada LTDKMDA | $180m | 12.1% | 11.2% | 7.6% | 2025 |
| 49 | Liquidia CorpLQDA | $158m | 1031.2% | −43.5% | −111.1% | 2025 |
| 50 | Heron Therapeutics, Inc.HRTX | $155m | 7.4% | −13.0% | — | 2025 |
| 51 | Cronos Group Inc.CRON | $147m | 24.6% | −6.4% | −0.9% | 2025 |
| 52 | Natural Alternatives International IncNAII | $143m | 9.7% | −14.5% | −35.0% | 2026 |
| 53 | Niagen Bioscience, Inc.NAGE | $129m | 29.9% | 13.4% | 28.3% | 2025 |
| 54 | Gyre Therapeutics, Inc.GYRE | $117m | 10.2% | 8.5% | 15.7% | 2025 |
| 55 | Zevra Therapeutics, Inc.ZVRA | $106m | 350.9% | 78.2% | 85.7% | 2025 |
| 56 | Eton Pharmaceuticals, Inc.ETON | $80m | 104.9% | −5.8% | −18.2% | 2025 |
| 57 | Rockwell Medical, Inc.RMTI | $69m | −31.8% | −7.7% | −15.3% | 2025 |
| 58 | Journey Medical CorpDERM | $62m | 10.2% | −18.5% | −44.0% | 2025 |
| 59 | Aytu Biopharma, IncAYTU | $58m | −13.3% | −24.8% | −52.6% | 2026 |
| 60 | Aquestive Therapeutics, Inc.AQST | $45m | −22.6% | −188.1% | — | 2025 |
| 61 | Cumberland Pharmaceuticals IncCPIX | $45m | 17.6% | −6.4% | −11.9% | 2025 |
| 62 | Biofrontera Inc.BFRI | $42m | 11.7% | −25.3% | −141.3% | 2025 |
| 63 | IM Cannabis Corp.IMCC | $39m | −0.7% | −20.7% | — | 2025 |
| 64 | BGM Group Ltd.BGM | $38m | 51.1% | −52.6% | −9.2% | 2025 |
| 65 | Sunshine Biopharma Inc.SBFM | $36m | 4.1% | −16.5% | −25.7% | 2025 |
| 66 | Verrica Pharmaceuticals Inc.VRCA | $36m | 370.2% | −50.3% | — | 2025 |
| 67 | Eyepoint, Inc.EYPT | $31m | −27.5% | −739.4% | −72.2% | 2025 |
| 68 | Scilex Holding CoSCLX | $30m | −46.5% | −1236.4% | — | 2025 |
| 69 | Sol-gel Technologies Ltd.SLGL | $19m | 68.0% | −31.6% | −23.7% | 2025 |
| 70 | Pelthos Therapeutics Inc.PTHS | $17m | — | −257.9% | — | 2025 |
| 71 | Zhengye Biotechnology Holding LtdZYBT | $16m | −37.5% | −60.0% | −26.0% | 2025 |
| 72 | Jaguar Health, Inc.JAGX | $12m | −1.5% | −465.4% | — | 2025 |
| 73 | China Pharma Holdings, Inc.CPHI | $4m | −8.5% | −76.9% | −20.9% | 2025 |
| 74 | Therapeuticsmd, Inc.TXMD | $3m | 71.6% | −18.8% | −2.1% | 2025 |
| 75 | Traws Pharma, Inc.TRAW | $3m | 1134.5% | 328.7% | — | 2025 |
| 76 | Nutriband Inc.NTRB | $2m | −4.8% | −404.1% | −125.6% | 2026 |
| 77 | Lipocine Inc.LPCN | $2m | −82.3% | −487.1% | −54.3% | 2025 |
| 78 | China SXT Pharmaceuticals, Inc.SXTC | $1m | −34.6% | −545.2% | −27.5% | 2026 |
| 79 | 60 Degrees Pharmaceuticals, Inc.SXTP | $1m | 65.5% | −732.5% | −196.4% | 2025 |
| 80 | Scienture Holdings, Inc.SCNX | $431,609 | 215.9% | −9618.0% | −55.6% | 2025 |
| 81 | Vyome Holdings, IncHIND | $319,714 | −96.0% | −3209.7% | — | 2025 |
| 82 | Akanda Corp.AKAN | $258,075 | −69.2% | −467.1% | — | 2025 |
| 83 | Gelteq LtdGELS | $107,317 | 99.7% | −4011.9% | −37.7% | 2025 |
| 84 | Talphera, Inc.TLPH | $28,000 | — | −51035.7% | −114.2% | 2025 |
| 85 | PRF Technologies Ltd.PRFX | $17,000 | — | −29541.2% | −96.9% | 2025 |
| 86 | Aspire-lakewood Holdings, Inc.ASBP | $6,202 | — | −394725.1% | — | 2025 |
Other health care industries
- Managed Health Care8 companies
- Health Care Distributors9 companies
- Health Care Services48 companies
- Health Care Equipment153 companies
- Biotechnology268 companies
- Life Sciences Tools & Services60 companies
- Health Care Facilities13 companies
- Hospitals5 companies
- Health Care Supplies13 companies
- Health Care Technology26 companies